Collegium Pharmaceutical, Inc. (FRA:354)

Collegium Pharmaceutical Statistics

Total Valuation

FRA:354 has a market cap or net worth of EUR 1.27 billion. The enterprise value is 1.83 billion.

Market Cap	1.27B
Enterprise Value	1.83B

Important Dates

The next estimated earnings date is Friday, February 27, 2026.

Earnings Date	Feb 27, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	31.61M
Shares Outstanding	n/a
Shares Change (YoY)	-13.26%
Shares Change (QoQ)	+0.93%
Owned by Insiders (%)	0.82%
Owned by Institutions (%)	104.48%
Float	26.91M

Valuation Ratios

The trailing PE ratio is 25.55 and the forward PE ratio is 4.99.

PE Ratio	25.55
Forward PE	4.99
PS Ratio	1.97
PB Ratio	5.43
P/TBV Ratio	n/a
P/FCF Ratio	5.16
P/OCF Ratio	5.13
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 5.24, with an EV/FCF ratio of 7.44.

EV / Earnings	36.81
EV / Sales	2.81
EV / EBITDA	5.24
EV / EBIT	12.15
EV / FCF	7.44

Financial Position

The company has a current ratio of 1.36, with a Debt / Equity ratio of 3.41.

Current Ratio	1.36
Quick Ratio	1.15
Debt / Equity	3.41
Debt / EBITDA	2.31
Debt / FCF	3.24
Interest Coverage	2.04

Financial Efficiency

Return on equity (ROE) is 22.96% and return on invested capital (ROIC) is 8.97%.

Return on Equity (ROE)	22.96%
Return on Assets (ROA)	6.75%
Return on Invested Capital (ROIC)	8.97%
Return on Capital Employed (ROCE)	15.16%
Revenue Per Employee	1.81M
Profits Per Employee	139,527
Employee Count	357
Asset Turnover	0.47
Inventory Turnover	2.35

Taxes

In the past 12 months, FRA:354 has paid 19.10 million in taxes.

Income Tax	19.10M
Effective Tax Rate	27.72%

Stock Price Statistics

The stock price has increased by +33.78% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+33.78%
50-Day Moving Average	32.36
200-Day Moving Average	28.48
Relative Strength Index (RSI)	71.01
Average Volume (20 Days)	43

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	12.38

Income Statement

In the last 12 months, FRA:354 had revenue of EUR 645.25 million and earned 49.81 million in profits. Earnings per share was 1.39.

Revenue	645.25M
Gross Profit	568.92M
Operating Income	149.14M
Pretax Income	68.91M
Net Income	49.81M
EBITDA	341.92M
EBIT	149.14M
Earnings Per Share (EPS)	1.39

Balance Sheet

The company has 243.64 million in cash and 797.98 million in debt, giving a net cash position of -554.34 million.

Cash & Cash Equivalents	243.64M
Total Debt	797.98M
Net Cash	-554.34M
Net Cash Per Share	n/a
Equity (Book Value)	234.22M
Book Value Per Share	7.41
Working Capital	137.17M

Cash Flow

In the last 12 months, operating cash flow was 247.95 million and capital expenditures -1.38 million, giving a free cash flow of 246.57 million.

Operating Cash Flow	247.95M
Capital Expenditures	-1.38M
Free Cash Flow	246.57M
FCF Per Share	n/a

Margins

Gross margin is 88.17%, with operating and profit margins of 23.11% and 7.72%.

Gross Margin	88.17%
Operating Margin	23.11%
Pretax Margin	10.68%
Profit Margin	7.72%
EBITDA Margin	52.99%
EBIT Margin	23.11%
FCF Margin	38.21%

Dividends & Yields

FRA:354 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	13.26%
Shareholder Yield	13.26%
Earnings Yield	3.91%
FCF Yield	19.38%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:354 has an Altman Z-Score of 1.31 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.31
Piotroski F-Score	8